

## Search strategy on PubMed

|     |  |
|-----|--|
| #1  | "PCSK9 Inhibitors"[Mesh]   |
| #2  | PCSK9i OR 'PCSK9 antibody' OR anti-PCSK  |
| #3  | 'Proprotein convertase subtilisin/kexin type 9' AND Inhibitor  |
| #4  | Evolocumab OR Repatha OR AMG145 OR 'AMG 145' OR Alirocumab OR REGN727 OR 'REGN 727' OR SAR-236553 OR 'SAR 236553' OR Praluent OR Bococizumab OR RN316 OR 'RN316' OR PF04950615 OR 'PF 04950615' OR Inclisiran OR 'ALN-PCS/OR ALN-PCScS' OR RG7652 OR 'RG 7652' OR LY3015014 OR 'LY 3015014' OR MEDI4166 OR 'MEDI 4166' OR AT04A OR AT06A |
| #5  | #1 OR #2 OR #3 OR #4   |
| #6  | "C-Reactive Protein"[Mesh]   |
| #7  | hsCRP/OR High Sensitivity C-Reactive Protein   |
| #8  | "Cytokines"[Mesh]  |
| #9  | Tumor Necrosis Factor-alpha/OR TNF alpha/OR TNF- $\alpha$ /OR Interleukins/OR IL-6/OR Interleukin 6/OR hs-IL-6   |
| #10 | "Leukocytes"[Mesh]   |
| #11 | monocyte/OR lymphocyte/OR WBC  |
| #12 | Arterial wall inflammation/OR most diseased segment/OR MDS/OR target-to-background ratio/OR TBR  |
| #13 | #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12  |
| #14 | randomized controlled trial  |
| #15 | controlled clinical trial  |
| #16 | randomized   |
| #17 | Placebo  |
| #18 | Randomly   |
| #19 | Trial  |
| #20 | Groups   |
| #21 | #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20  |
| #22 | #5 AND #13 AND #21   |